Avenacy Announces Launch of Magnesium Sulfate in Water for Injection in the U.S. Market

May 14, 2024

Represents the Company’s eighth product launch since inception in October 2023.

SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Magnesium Sulfate in Water for Injection in the United States as approved by the U.S. Food and Drug Administration. Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously, it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Avenacy’s Magnesium Sulfate in Water for Injection is available in Ready-to-Use Premix IV bags in multiple formulations: 2g/50mL (40mg/mL), 4g/100mL (40mg/mL), and 4g/50mL (80mg/mL). In line with Avenacy’s mission to champion patient safety and streamline patient care, Magnesium Sulfate in Water for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Additionally, the Ready-to-Use presentation is expected to help reduce dosing inaccuracies, enhance patient safety, and streamline inventory.

“As a vital product for healthcare providers, Magnesium Sulfate represents a large market opportunity for Avenacy, and we are excited to deliver this ready-to-use product to hospitals all over the country as a means to improve patient care,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “Since launching seven months ago, we have seen very encouraging early traction of Avenacy’s products in the market, and we are proud to be launching our eighth product as we continue to scale up our business in order to meet demand for our injectable medications.”

Avenacy will partner with Milla Pharmaceuticals Inc., (“Milla Pharmaceuticals”), the U.S. subsidiary of global generic and pharmacy service player A.forall (“A.forall”), to begin shipping Magnesium Sulfate in Water for Injection to wholesale partners this week. Milla Pharmaceuticals is part of Avenacy’s global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.

“We’re excited to work with Avenacy to introduce Magnesium Sulfate in Water for Injection to the market,” said Erik Lazarich, President of A.forall’s U.S. Operations, “Delivering this ready-to-use product to hospitals nationwide is a key step in improving patient care and advancing our mission of making affordable medicines available to all.”

Magnesium Sulfate in Water for Injection had U.S. sales of approximately $37.0 million for the twelve months ending in June 2023.1

Please see link for Full Prescribing Information.

1Source: IQVIA

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit  https://www.avenacy.com.

About Milla Pharmaceuticals, an A.forall company

Milla Pharmaceuticals Inc., an A.forall company, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market focused on niche injectable and solution products for hospitals and clinics.

More info: Milla Pharmaceuticals & A.forall – Making Affordable Medicines Available To All.

Media Contact

FTI Consulting Avenacy@fticonsulting.com